论文信息 - 203PA phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5) - 字舞流文

203PA phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5)

N. Sugimoto | D. Sakai | Y. Kurokawa | T. Shimokawa | J. Kawada | R. Kawabata | T. Sato | K. Fujitani | Y. Kimura | J. Matsuyama | K. Nishikawa | H. Hasegawa | S. Endo | Y. Oka | T. Kawase | T. Shimizu | Junichi Nishijima | Yutaka Isozaki | Y. Oka | T. Shimizu | T. Sato | J. Nishijima | Y. Isozaki | T. Sato | J. Nishijima